

BeiGene is bringing a state-of-the-art manufacturing and clinical R&D center to New Jersey.

Who are we?

BeiGene is a global biotechnology company that is discovering and developing innovative cancer medicines that are accessible and affordable to more patients around the world.

Advancing Health Equity & Our Global Footprint

Harnessing Science to Improve Access, Equity and Affordability

~800,000 patients reached worldwide

17
Approved Medicines*



65+
Markets where BRUKINSA® (zanubrutinib) is Approved

10k+
Colleagues Globally in Over 40 Offices on 5 Continents



80%
of the World's Cancers by Incidence Covered by Our Broad Pipeline

Building A Dedicated Research & Development Program

A Goal to Deliver First-in-Class & Best-in-Class Therapies with

1,100+ oncology researchers

140+
Clinical Trials Initiated in 45+ Countries and Regions



~50
Clinical and Commercial Assets

20k+
Patients Enrolled



60+
Preclinical Programs, the Majority with First-in-Class Potential

*Includes partner company products



What is our vision for the future?

The Princeton West Innovation Campus will house a state-of-the-art, clinical- and commercial-stage biologics manufacturing facility and clinical R&D center, which complement BeiGene's existing capabilities around the world.

42-acre
biologics site



Breaking Ground
in April 2022,
construction expected
to be completed in
2024



~100 jobs
created in the region
with a plan to hire
hundreds more



400,000 sq ft
of dedicated commercial-
stage biologic pharmaceutical
manufacturing space with the
ability to expand an additional
700,000 sq ft



~\$800 million
investment into the site to
support growth in the biotech
sector in New Jersey

How do we make a difference?



BeiGene is committed to making a significant investment in New Jersey - beyond construction and staffing - to ensure it is a responsible and positive force in the community.



The company is actively working with local businesses, government, community groups, academic institutions, hospitals, and cancer-focused non-profits.



BeiGene is investing in sustainability measures both in the constructed buildings and surrounding 42 acres.

This infographic contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's Princeton West Innovation Campus. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors including those risks discussed in the section entitled "Risk Factors" in BeiGene's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this infographic is as of September 1, 2023, and BeiGene undertakes no duty to update such information unless required by law.